London, United Kingdom
Research view
Retinitis pigmentosa: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
EU-13 is a filter, not a ranking: it only narrows the list.
Tübingen, Germany
Cambridge, United States
Paris, France
Paris, France
Oxford, United Kingdom
Nijmegen, Netherlands
Baltimore, United States
London, United Kingdom
Boston, United States
New York, United States
Beijing, China
Bethesda, United States
Bethesda, United States
Paris, France
Shanghai, China
Shanghai, China
Paris, France
Basel, Switzerland
Basel, Switzerland
London, United Kingdom
New York, United States
Seoul, South Korea
Irvine, United States
24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Suspended
“IRB renewal lapsed”Registry text, quoted unchanged. Source
Withdrawn
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)
“Lack of funding.”Registry text, quoted unchanged. Source
Terminated
A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa
“The study stopped because patients dropped out of the study to participate in the interventional trials. With interventional trials present there is very little interest in participating in a Natural Histoy study.”Registry text, quoted unchanged. Source
Terminated
Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)
“Unable to recruit additional participants after multiple extensions to planned enrollment period.”Registry text, quoted unchanged. Source
Terminated
“Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.”Registry text, quoted unchanged. Source
Withdrawn
RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa
“unavailability of the investigational device”Registry text, quoted unchanged. Source
Withdrawn
PMCF Study for Partial Vision Restoration Using the Subretinal Implant RETINA IMPLANT Alpha AMS
“Manufacturer of the investigational device has ceased all business activities”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 1
- Organoids 11
- Mendelian Randomization Analysis 3
- CRISPR-Cas Systems 5
- Gene Expression Profiling 9
- Sequence Analysis, RNA 1
- Whole Genome Sequencing 1
- Exome Sequencing 19
- Proteomics 3
- Metabolomics 1
- Mass Spectrometry 1
- Immunohistochemistry 9
- Magnetic Resonance Imaging 3
- Machine Learning 1
- Deep Learning 2
- Cohort Studies 5
- Genome-Wide Association Study 5
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.